Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor
Use
This test is useful for identifying mutations and rearrangements that may support a diagnosis or help determine prognosis for patients with central nervous system tumors. It can identify specific mutations and rearrangements within genes known to be associated with response or resistance to specific cancer therapies. The test evaluates somatic mutations within 89 genes associated with central nervous system tumors, and gene fusions within 1445 genes.
Special Instructions
Not provided.
Limitations
This test cannot reliably differentiate between somatic and germline alterations. Negative results do not rule out the presence of variants below the limits of detection, with analytical sensitivity at 5% mutant allele frequency for sequence alterations and a minimum coverage of 500X for sequence. It cannot detect multi-exon deletions, duplications, or genomic copy number variants. It may not detect fusions involving non-targeted genes or deep intronic regions.
New York Approved
Methodology
NGS
Biomarkers
No genes
GeneNo genes
GeneNo genes
Gene
LOINC Codes
- 73977-1 - Cancer multigene analysis Bld/T
- 50397-9 - Mol dx interp Bld/T Ql
- 82939-0 - Genetic variant details Bld/T
- 69047-9 - Geneticist review
- 48767-8 - Annotation comment Imp
- 31208-2 - Specimen source
- 80398-1 - Unique ID Current sample
- 18771-6 - Provider signing name
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with an acceptable amount of tumor tissue or slides as specified. Minimum tumor area is 72 mm2.